Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Sagimet Biosciences Inc.NASDAQ: SGMT

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns positive

Q1 FY2026 change in working capital was $301K, compared with -$726K a year earlier. Trailing-twelve-month change in working capital was -$3.42M.

Context

  • Change in working capital increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near $301K or moves back toward the trailing-twelve-month quarterly average of -$854K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$301K+107.0% QoQ
Last fiscal yearDec 2025
-$1.05M+0.5% YoY
LTMMar 2026
-$3.42M-181.2% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+141.5%——
1 year+0.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(1.05M) USD
Year-over-year change
-0.5%

Change in Working Capital vs competitors

How SGMT compares with its peers on the latest reported figures

  • SGMT's LTM Mar 2026 change in working capital of $3.42M is the 9th largest of the 11 companies compared; the peer median is $7.29M.
  • Its year-over-year change of -181.2% is the 9th highest of 11, against a peer median of -20.9%.
SGMT Competitors Peer median
Change in Working Capital for SGMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASMBAssembly Biosciences, Inc.LTM Mar 2026$36.78M +105.8%+162.3%51.7%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$31.04M -3.9%—110.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$26.75M -37.9%—73.3%
HUMAHumacyte, Inc.LTM Mar 2026$15.14M +208.6%—750.8%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$14.08M +115.1%-24.4%245.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$13.89M +159.9%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$8.51M -85.7%+46.2%18.8%
ZURAZura Bio LimitedLTM Mar 2026$6.07M -215.8%——
SGMTSagimet Biosciences Inc.LTM Mar 2026$3.42M -181.2%——
IMRXImmuneering CorporationLTM Mar 2026$1.66M -293.7%+30.6%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$531K -62.5%——
Peer median (excluding SGMT) $7.29M-20.9%+38.4%91.6%

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Depreciation & Amortization0130K000
Deferred Income Tax00000
Stock-Based Compensation1.9M1.88M4.99M5.29M6.45M
Change in Working Capital(55K)4.21M(978K)(1.05M)(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables00120K(907K)929K
Other Working Capital(55K)4.21M(1.1M)(141K)(1.98M)
Other Non-Cash Items883K(215K)98K(1.11M)(8K)
Operating Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments0(41.45M)(19.62M)(108.09M)(106.86M)
Sales of Investments09.44M32.2M46.4M111.42M
Other Investing Activities00000
Investing Cash Flow0(32.01M)12.58M(61.68M)4.56M
Debt Repayment00000
Common Stock Issued012K89.68M105.75M275K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.07M)(85K)(3.51M)(931K)0
Financing Cash Flow9.74M(73K)86.17M104.82M275K
Effect of Forex Changes00000
Net Change in Cash(11.97M)(56.57M)74.98M701K(40.82M)
Free Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.